Assessment of Effect of Rapastinel on Driving Performance

Completed · Phase 1 · Has a placebo group

Conditions studied: Driving Performance

In brief

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.

Key facts

Study ID
NCT03814733
Run by
Naurex, Inc, an affiliate of Allergan plc
People needed
107
Starts
2018-11-05
Expected to finish
2019-04-03
Last updated by the study team
2019-07-11

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.